Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease

Table 4

Incidences of major adverse cardiac events in the 3- and 12-month DAPT groups.

	3-month DAPT; (88 lesions)	12-month DAPT; (81 lesions)	𝑃-value
MACE, n (%)	10 (11.4)	9 (11.1)	NS
Death (all causes), n (%)	0 (0)	1 (1.2)	NS
Cardiac death, n (%)	0 (0)	1 (1.2)	NS
MI (all causes), n (%)	2 (2.3)	1 (1.2)	NS
Q-MI, n (%)	1 (1.1)	1 (1.2)	NS
Non-Q-MI, n (%)	1 (1.1)	0 (0)	NS
Cerebrovascular accident, n (%)	0 (0)	1 (1.2)	NS
TLR, n (%)	8 (9.1)	8 (9.9)	NS
TVR, n (%)	8 (9.1)	8 (9.9)	NS

DAPT: dual antiplatelet therapy; MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularization; TVR: target vessel revascularization; NS: not significant.